Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN393422 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Ezrin (EZR) (AA 1-587) antibody
- Antibody type
- Monoclonal
- Description
- This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Mouse
- Epitope
- AA 1-587
- Isotype
- IgG
- Antibody clone number
- 1E11
- Vial size
- 100 μg
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Submitted references Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors.
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".
Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
Ezrin immunoreactivity in renal cell carcinomas.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators.
Diabetes care 2010 Oct;33(10):2250-3
Diabetes care 2010 Oct;33(10):2250-3
Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors.
Machado I, Navarro S, Giner F, Alberghini M, Bertoni F, Llombart-Bosch A
Virchows Archiv : an international journal of pathology 2010 Jul;457(1):87-9
Virchows Archiv : an international journal of pathology 2010 Jul;457(1):87-9
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".
Johnatty SE, Beesley J, Chen X, Macgregor S, Duffy DL, Spurdle AB, deFazio A, Gava N, Webb PM, Rossing MA, Doherty JA, Goodman MT, Lurie G, Thompson PJ, Wilkens LR, Ness RB, Moysich KB, Chang-Claude J, Wang-Gohrke S, Cramer DW, Terry KL, Hankinson SE, Tworoger SS, Garcia-Closas M, Yang H, Lissowska J, Chanock SJ, Pharoah PD, Song H, Whitemore AS, Pearce CL, Stram DO, Wu AH, Pike MC, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Anton-Culver H, Ziogas A, Hogdall E, Kjaer SK, Hogdall C, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Phelan CM, Sellers TA, Cunningham JM, Vierkant RA, Rider DN, Goode EL, Haviv I, Chenevix-Trench G, Ovarian Cancer Association Consortium., Australian Ovarian Cancer Study Group., Australian Cancer Study (Ovarian Cancer).
PLoS genetics 2010 Jul 8;6(7):e1001016
PLoS genetics 2010 Jul 8;6(7):e1001016
Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
Boldrini E, Peres SV, Morini S, de Camargo B
Journal of pediatric hematology/oncology 2010 Aug;32(6):e213-7
Journal of pediatric hematology/oncology 2010 Aug;32(6):e213-7
Ezrin immunoreactivity in renal cell carcinomas.
Tuna B, Yorukoglu K, Mazzucchelli R, Mungan U, Secil M, Montironi R, Kirkali Z
Analytical and quantitative cytology and histology 2009 Oct;31(5):340-4
Analytical and quantitative cytology and histology 2009 Oct;31(5):340-4
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- ELISA
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC